NGM Bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) Announces CEO Participation in Evercore ISI HealthCONx Conference and Jefferies London Healthcare Conference

Positive

• NGM Bio CEO to present company overview and business update at Evercore ISI HealthCONx Conference
• Participation in investor meetings at Jefferies London Healthcare Conference indicates focus on investor relations and potential business opportunities

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming 6^th Annual Evercore ISI HealthCONx Conference and will present an overview of the company and provide a business update. Management will also be available for investor meetings at the upcoming Jefferies London Healthcare Conference.

Jefferies London Healthcare Conference 2023
November 14 – 16, 2023

6th Annual Evercore ISI HealthCONx Conference
Wednesday, November 29, 2023, 8:45 am ET

About NGM Bio
NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. Visit us at www.ngmbio.com for more information.

Investor Contact:
ir@ngmbio.com

Media Contact:
media@ngmbio.com

 

 

 

FAQ

What is the latest announcement from NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM)?

NGM Bio announced CEO participation in fireside chat at Evercore ISI HealthCONx Conference and investor meetings at Jefferies London Healthcare Conference.

When and where will the CEO of NGM Bio be presenting at the upcoming conferences?

The CEO will present at the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023, and will be available for investor meetings at the Jefferies London Healthcare Conference from November 14-16, 2023.

What is the focus of NGM Bio's participation in these conferences?

NGM Bio aims to provide an overview of the company, deliver a business update, and engage in investor meetings to explore potential opportunities.

Why is NGM Bio's participation in the conferences important?

NGM Bio's participation demonstrates a commitment to investor relations and potential business growth.

How will NGM Bio's participation impact its stock performance?

Participation in these conferences can enhance investor confidence and potentially lead to new business partnerships, impacting stock performance positively.